Metsera Pipeline | Advancing Next-Gen Obesity Therapies Explore Metsera's pipeline of innovative NuSH therapies From oral to injectable solutions, we aim to deliver best-in-class potency, durability, and scalability for obesity treatment
IND Activity | FDA IND ActivityHome Drugs Development Approval Process | Drugs How Drugs are Developed and Approved Drug and Biologic Approval and IND Activity Reports IND Activity
D D Pharmatech, Metsera expand collaboration for new obesity . . . - KBR D D Pharmatech will continue preclinical development necessary for Investigational New Drug (IND) submissions, while Metsera will support all related costs, promising stable revenue generation for D D Pharmatech beyond milestone payments
Drug and Biologic Approval and IND Activity Reports | FDA The list also includes a link to investigational new drug (IND) activity reports For Center for Biologic Evaluation and Research (CBER) BLA approvals, please visit: CBER Approvals by Year
IND Application Procedures: Overview | FDA Once an IND application is in effect, a drug manufacturer may ship the investigational new drug to the investigator (s) named in the application
Drug Approvals and Databases | FDA CDER highlights key Web sites Web page provides quick links to everything from acronyms to wholesale distributor and third-party logistics providers reporting